Chronic complex regional pain syndrome patient IgM has pronociceptive effects in the spinal cord, but not skin, of fracture mice

Pain is often a warning system, a signal that tissue is damaged and needs protection. But in a condition called complex regional pain syndrome, or CRPS, that warning system goes into overdrive long after the injury has healed. A broken bone or a minor burn can trigger months or years of burning pain, swelling, and extreme sensitivity to touch in a limb that looks normal to the eye. For decades, doctors have struggled to understand why this happens, and why it is so difficult to treat. A leading theory suggests that the body's immune system, which usually fights off bacteria and viruses, mistakenly turns against the body's own tissues. Specifically, researchers suspect that certain immune proteins, known as antibodies, are binding to the body's own cells and keeping the pain signals switched on.

The immune system has many different types of weapons, including a large, heavy antibody called IgM. Think of IgM as a massive, five-armed starfish floating in the blood. Because it is so large, it generally cannot easily squeeze through the tight walls of blood vessels to enter delicate tissues like the skin or the spinal cord. However, when the immune system is confused, as it is in CRPS, these antibodies might find a way to cause trouble. The central question for scientists has been: do these rogue antibodies attack the skin of the injured limb, the spinal cord where pain signals are processed, or both? And does this attack change as the disease moves from its early stages to a chronic, long-term state?

A team of researchers from the United States, the United Kingdom, and Germany has now provided a clear answer to this question by using a specialized mouse model of the disease. They worked with mice that had broken their leg bones and were missing their own immune system, meaning they could not produce any antibodies of their own. This allowed the scientists to act as a clean slate, injecting them with blood components from human patients to see exactly what those components would do. The researchers focused on patients who had suffered from CRPS for more than a year, a stage where the pain is often stubborn and resistant to standard treatments.

When the scientists took the IgM antibodies from these chronic patients and injected them directly into the spinal fluid of the mice, the results were immediate and dramatic. Within one hour, the mice developed severe pain sensitivity in their injured leg, flinching at light touches they had previously ignored. They also stopped putting weight on that leg, a clear sign of significant discomfort. This happened every single time, with antibodies from all ten chronic patients tested. However, when the researchers injected the exact same antibodies directly into the skin of the mice's injured foot, nothing happened. The pain did not increase. This finding was a major clue: in the chronic stage of the disease, the problematic antibodies were targeting the spinal cord, not the skin.

To understand why this mattered, the team looked at what these antibodies were actually grabbing onto inside the body. They discovered that the IgM from chronic patients had a strong attraction to a specific protein called GFAP, which is found in the support cells of the spinal cord. When the researchers injected a synthetic version of an antibody that targets this GFAP protein directly into the spinal fluid of the mice, it caused the same rapid pain response. This confirmed that the antibodies were indeed latching onto the spinal cord's support structure. In contrast, when they injected the anti-GFAP antibodies into the skin, the mice felt no extra pain. This suggested that over time, the immune system in CRPS patients shifts its focus. In the early stages of the disease, the antibodies attack both the skin and the spinal cord, but as the condition becomes chronic, the attack seems to concentrate almost entirely on the spinal cord.

The researchers also investigated why injecting the antibodies into the bloodstream did not cause pain in the skin, but did cause pain when injected into the spinal fluid. They suspected the size of the IgM antibody was the barrier. Because the antibody is so large, it struggles to cross the blood-spinal cord barrier, a protective wall that keeps the spinal cord safe from the rest of the body. To test this, they used a safe chemical to temporarily open the gaps in this barrier. When they injected the chronic patient antibodies into the bloodstream and then opened the barrier, the pain appeared within an hour, just as it did with the direct spinal injection. This proved that the antibodies were capable of causing pain in the spinal cord, but they simply could not get there fast enough through normal circulation to cause the rapid skin pain seen in early disease.

Finally, the team traced the chain reaction that followed the antibody binding. They found that once the IgM antibodies latched onto the spinal cord, they triggered a cascade of events involving the body's complement system, a part of the immune response that acts like a chemical alarm. This alarm activated tiny immune cells in the spinal cord called microglia, which then released inflammatory chemicals known as cytokines. These chemicals are the actual agents that turn up the volume on pain signals. When the researchers blocked the complement alarm or stopped the release of these inflammatory chemicals, the pain response vanished completely, even when the antibodies were present.

This work paints a detailed picture of how chronic pain can become a self-sustaining loop driven by the immune system. It suggests that in long-term CRPS, the pain is not coming from the injured limb itself, but from the spinal cord, where the immune system has learned to attack the body's own support cells. The findings offer a potential explanation for why amputation sometimes fails to relieve the pain in these patients; if the problem is in the spinal cord, removing the limb does not remove the source of the pain. By identifying the specific target in the spinal cord and the chemical pathway that follows, the study points toward new ways to treat this debilitating condition, focusing on stopping the immune attack at the level of the spinal cord rather than just managing the symptoms in the limb.